P3AGI · Public Private Partnership for Asthma Imaging and Genomics

The main objective of this project is to develop a research network that includes both private and public institutions focused on the exchange of expertise in imaging, genomics and bioinformatics to be utilized in monitoring therapies and disease progression in severe allergic asthma (AA): • Aeirtec, a research-service SME with Hu-SCID in vivo models of AA that would benefit from academic expertise in high tech imaging and immunology • Marinomed, an SME with novel compounds potentially relevant to AA, in need of in vivo models as well as genomics and imaging technologies aimed at validating its compounds • CBM, an SME with expertise in genomics as well as IP exploitation and business development, managing a biotech cluster, in need of furthering its imaging expertise as well as its competence in AA models • UMG-GOE is a university which provides strong expertise in the imaging field, in need of bioinformatics support as well as specific expertise on AA models • MUW is an academic partner with expertise in in vivo models of AA and in the basic immunology underlying the disease that will advance their research objectives with novel therapeutics to study and from expertise in genomics and imaging. The combined expertise and transfer of knowledge between academic and industrial partners will have an impact on the scientific community and on exploitation and commercialization.The main scientific and technological objectives will encompass: 1. Development of novel optical imaging techniques and genomic biomarkers for severe AA 2. Identification of potential biomarkers useful for clinical monitoring of therapeutic efficacy of novel compounds in ththe treatment of severe AA 3. Development of novel high resolution molecular imaging techniques in animal models of AA 4. Bioinformatics support in the acquisition, management, archiving, and analysis of imaging and genomics data